keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine. |
In vitro | The KRAS G13D peptide (25 mer) is encoded by an immunomodulatory therapeutic mRNA, which can serve in the development of a KRAS vaccine [1]. |
Synonyms | KRAS G13D peptide, 25 mer |
Molecular Weight | 2634.13 |
Formula | C118H201N29O36S |
CAS No. | 145019-94-9 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KRAS G13D peptide, 25 mer 145019-94-9 KRAS G-13D peptide, 25 mer inhibitor inhibit